Indeed, the pan-LOX inhibitor PXS-5505 (Yao et al., 2022) and the LOXL2/3 inhibitor PXS-5153A (Schilter et al., 2019) have been proven to have anti-hepatic fibrosis properties, among which PXS-5505 is currently undergoing clinical trials (NCT04676529), indicating that LOX is still a target worth developing to treat fibrosis. The gene discussed is LOXL2; the disease is Hepatic fibrosis.